STRO Sutro Biopharma, Inc. - Common Stock
$22,94
Kurs · Aug 19, 2026
Fundamentaldaten per Aug 12, 2026
52W-Spanne
$1–$44
51% of range
Analystenbewertung
BUY
19 analysts
Kursziel
$48
+108% upside
P/E (TTM)
-1.0
ROE
232.2%
Nettogewinnmarge
-186.5%
Über Sutro Biopharma, Inc. - Common Stock Unternehmensübersicht von Wikipedia
Sutro Biopharma Inc. ist ein US-amerikanisches Biotechnologieunternehmen mit Sitz in South San Francisco, Kalifornien, das im Jahre 2003 gegründet wurde, zunächst unter dem Namen Fundamental Applied Biology. 2009 wurde der Firmenname in Sutro Biopharma geändert. Die Aktie ist an der amerikanischen Börse NASDAQ gelistet.
Mehr lesen
Sutro Biopharma Inc. ist ein US-amerikanisches Biotechnologieunternehmen mit Sitz in South San Francisco, Kalifornien, das im Jahre 2003 gegründet wurde, zunächst unter dem Namen Fundamental Applied Biology. 2009 wurde der Firmenname in Sutro Biopharma geändert. Die Aktie ist an der amerikanischen Börse NASDAQ gelistet.
Das Unternehmen befasst sich mit der Entwicklung von Krebs- und Autoimmuntherapeutika der nächsten Generation-Antikörperkonjugate, bispezifische Antikörper und Zytokinderivate. Ohne Einschränkung durch traditionelle Methoden der zellbasierten Entdeckung wird versucht, zielgerichtete Medikamente zu entwickeln, indem außerhalb der Einschränkungen der Zelle geforscht wird.
Entwicklungen
Sutro Biopharma hat die Chemoimmunkonjugate (Antibody-drug conjugate – ADC) STRO-001 und STRO-002 entwickelt. STRO-001 wird zurzeit in einer klinischen Phase-1-Studie für Patienten mit Multiplem Myelom untersucht.
STRO-002 wird zurzeit in einer klinischen Phase-1-Studie für Patientinnen mit Ovarialkarzinom (Eierstockkrebs) und Endometriumkarzinom untersucht und hat von der FDA (Lebensmittelüberwachungs- und Arzneimittelbehörde der Vereinigten Staaten) den Orphan-Drug-Status für Eierstockkrebs erhalten.
Ein dritter Produktkandidat, CC-99712, ein ADC, untersucht Patienten in seiner klinischen Phase-1-Studie mit multiplem Myelom auf und hat von der Food and Drug Administration den Orphan-Drug-Status erhalten.
Ein vierter Produktkandidat, M1231, ein ADC, nimmt Patienten für seine klinische Phase-1-Studie mit Patienten mit metastasierenden soliden Tumoren, nicht-kleinzelligem Lungenkrebs und Plattenepithelkarzinom der Speiseröhre auf.
Partnerschaften
Sutro Biopharma arbeitet unabhängig und mit Partnern an der Entwicklung neuartiger Krebstherapien. Diese sind Bristol-Myers Squibb, Merck KGaA, EMD Serono und Vaxccyte.
== Einzelnachweise ==
Quelle: Wikipedia, CC BY-SA 4.0 · Auf Wikipedia ansehen ↗
STRO Aktien-Snapshot Kurs, Marktkapitalisierung, P/E, EPS, ROE, Schulden/Eigenkapital, 52-Wochen-Spanne
Kurs
$22.94
Marktkapitalisierung
$197M
P/E (TTM)
-1.0
EPS (TTM)
$-22.49
Umsatz (TTM)
$102M
Dividendenrendite
—
ROE
232.2%
Verschuldungsgrad
—
52W-Spanne
$1 – $44
STRO Aktienkurs-Chart Täglich OHLCV mit technischen Indikatoren — Schwenken, Zoom und Ansicht anpassen
Configure
10-Jahres-Performance Umsatz-, Nettoergebnis-, Margen- und EPS-Trends
Umsatz & Nettoergebnis
$102M
2016-12-31
→
2025-12-31
EPS
$-22.49
2020-12-31
→
2025-12-31
Freier Cashflow
—
2018-12-31
→
2018-12-31
Margen
-186.5%
Bewertung P/E-, P/S-, P/B-, EV/EBITDA-Verhältnisse — ist die Aktie teuer oder günstig?
Kennzahl
5-Jahres-Trend
STRO
Peer-Median
P/E (TTM)
-1.0
6.1
P/S (TTM) (K/V (TTM))
1.9
7.7
P/B (K/B)
-1.5
2.2
Rentabilität Brutto-, Betriebs- und Nettomargen; ROE, ROA, ROIC
Kennzahl
5-Jahres-Trend
STRO
Peer-Median
Operating Margin (Betriebsgewinnmarge)
-154.5%
—
Net Profit Margin (Nettogewinnmarge)
-186.5%
-60.9%
ROA
-68.1%
-50.0%
ROE
232.2%
-44.8%
ROIC
119.5%
—
Finanzielle Gesundheit Verschuldung, Liquidität, Solvenz — Bilanzstärke
Kennzahl
5-Jahres-Trend
STRO
Peer-Median
Current Ratio (Liquiditätsgrad)
2.0
5.9
Quick Ratio
1.9
—
Wachstum Umsatz-, EPS- und Nettoergebniswachstum: YoY, 3-Jahres-CAGR, 5-Jahres-CAGR
Kennzahl
5-Jahres-Trend
STRO
Peer-Median
Revenue YoY (Umsatz YoY)
65.2%
—
Revenue CAGR 3Y (Umsatz CAGR 3J)
14.8%
—
Revenue CAGR 5Y (Umsatz CAGR 5J)
19.1%
—
Kapitaleffizienz Umsatz pro Vermögenswert, Lagerumschlag, Forderungsumschlag
Kennzahl
5-Jahres-Trend
STRO
Peer-Median
STRO Analysten-Konsens Bullische und bärische Analystenmeinungen, 12-Monats-Kursziel, Aufwärtspotenzial
KAUF
19 Analysten
- Starker Kauf 5 26,3%
- Kauf 12 63,2%
- Halten 1 5,3%
- Verkauf 1 5,3%
- Starker Verkauf 0 0,0%
12-Monats-Kursziel
13 Analysten · 2026-08-13
Median
$50.00
Jetzt
$22.94
Tief
$10.00
Hoch
$61.00
Median-Ziel
$50.00
+118,0%
Mittelwert-Ziel
$47.77
+108,2%
Ergebnisverlauf EPS Ist vs. Schätzung, Überraschung %, Beat-Rate, nächstes Ergebnisdatum
Durchschn. Überraschung
-0.34%
| Zeitraum | EPS Actual | EPS est. | Überraschung |
|---|---|---|---|
| 31. März 2026 | $-2.94 | $-3.85 | 0.91% |
| 31. Dezember 2025 | $-5.29 | $-4.43 | -0.86% |
| 30. September 2025 | $-6.70 | $-4.23 | -2.5% |
| 30. Juni 2025 | $-1.40 | $-4.10 | 2.7% |
| 31. März 2025 | $-9.10 | $-7.22 | -1.9% |
| 31. Dezember 2024 | $-8.90 | $-8.48 | -0.42% |
Peer-Vergleich (GICS-Subbranche) Wichtige Kennzahlen im Vergleich zu Branchenkollegen
| Ticker | Marktkapitalisierung | P/E | Umsatz Vj. | Nettomarge | ROE | Bruttogewinnmarge |
|---|---|---|---|---|---|---|
| STRO | $99M | -0.5 | 65.2% | -186.5% | 232.2% | — |
| ENTA | $256M | -3.1 | -3.4% | -125.4% | -103.5% | — |
| DMAC | $428M | — | — | — | -78.7% | — |
| GALT | $271M | -8.7 | — | — | 25.0% | — |
| ZNTL | $93M | -0.7 | — | — | -49.5% | — |
| IPSC | $87M | -7.1 | 1556.8% | -8.8% | -5.2% | — |
| SABS | — | — | — | — | — | — |
| ABEO | $290M | 5.2 | 147.5% | 1223.1% | 44.1% | — |
| IMRX | — | -5.2 | — | — | -45.3% | — |
Vollständige Fundamentaldaten Alle Kennzahlen nach Jahr — Gewinn- und Verlustrechnung, Bilanz, Cashflow
Gewinn- und Verlustrechnung 15
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $102M | $62M | $154M | $68M | $62M | $43M | $43M | $38M | $52M | |
| R&D Expense | $166M | $252M | $180M | $137M | $104M | $77M | $66M | $54M | $55M | |
| SG&A Expense | $41M | $48M | $63M | $60M | $56M | $37M | $33M | $21M | $16M | |
| Operating Expenses | $261M | $300M | $243M | $197M | $160M | $114M | $98M | $76M | $71M | |
| Operating Income | $-158M | $-238M | $-89M | $-129M | $-99M | $-71M | $-55M | $-37M | $-19M | |
| Interest Expense | · | · | · | · | · | · | · | $2M | $612.0K | |
| Other Non-op | · | · | · | · | · | · | · | $2M | $-77.0K | |
| Pretax Income | $-191M | $-225M | $-89M | $-117M | $-106M | $-32M | · | · | · | |
| Income Tax | $-93.0K | $2M | $18M | $2M | $0 | $103.0K | $0 | $0 | $0 | |
| Net Income | $-191M | $-227M | $-107M | $-119M | $-106M | $-32M | $-119M | $-35M | $-20M | |
| EPS (Basic) | $-22.49 | $-29.40 | $-1.78 | $-2.35 | $-2.29 | $-0.99 | · | · | · | |
| EPS (Diluted) | $-22.49 | $-29.40 | $-1.78 | $-2.35 | $-2.29 | $-0.99 | · | · | · | |
| Shares (Basic) | 8,497,798 | 7,736,734 | 60,163,542 | 50,739,185 | 46,119,089 | 32,573,469 | · | · | · | |
| Shares (Diluted) | 8,497,798 | 7,736,734 | 60,163,542 | 50,739,185 | 46,119,089 | 32,573,469 | · | · | · | |
| EBITDA | $-151M | $-231M | $-82M | $-123M | $-94M | $-67M | · | $-33M | · |
Bilanz 24
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $58M | $190M | $69M | $47M | $30M | $206M | $5M | $125M | $22M | |
| Short-term Investments | $83M | $127M | $264M | $255M | $130M | $120M | $113M | $79M | · | |
| Receivables | $4M | $9M | $36M | $7M | $12M | $6M | $6M | $2M | $2M | |
| Prepaid Expense | $6M | $18M | $10M | $12M | $8M | $4M | $4M | $3M | $2M | |
| Current Assets | $151M | $343M | $422M | $353M | $219M | $378M | $129M | $210M | $26M | |
| PP&E (Net) | $11M | $18M | $22M | $25M | $23M | $13M | $10M | $11M | $14M | |
| PP&E (Gross) | $38M | $67M | $64M | $63M | $56M | $50M | $43M | $40M | $39M | |
| Accum. Depreciation | $27M | $49M | $42M | $38M | $33M | $37M | $34M | $29M | $25M | |
| Other Non-current Assets | $495.0K | $7M | $4M | $2M | $2M | $2M | $3M | $2M | $1M | |
| Total Assets | $174M | $387M | $471M | $407M | $341M | $394M | $156M | $223M | $41M | |
| Accounts Payable | $8M | $10M | $9M | $5M | $6M | $6M | $6M | $3M | $3M | |
| Accrued Liabilities | $15M | $13M | $15M | $13M | $11M | $9M | $6M | $6M | $4M | |
| Current Liabilities | $75M | $132M | $94M | $67M | $42M | $30M | $33M | $36M | $32M | |
| Capital Leases | $8M | $16M | $23M | $30M | $31M | · | · | · | · | |
| Other Non-current Liabilities | $2M | $2M | $2M | $119.0K | $146.0K | $481.0K | $134.0K | $102.0K | $14.0K | |
| Total Liabilities | $306M | $343M | $321M | $190M | $89M | $62M | $59M | $92M | $47M | |
| Long-term Debt | · | · | $4M | $16M | $25M | $25M | · | $15M | · | |
| Total Debt | · | · | $4M | $16M | $25M | $25M | · | $10M | · | |
| Common Stock | $9.0K | $8.0K | $61.0K | $58.0K | $46.0K | $46.0K | $23.0K | $23.0K | · | |
| Retained Earnings | $-978M | $-787M | $-559M | $-453M | $-333M | $-228M | $-196M | $-150M | $-115M | |
| AOCI | $19.0K | $39.0K | $21.0K | $-618.0K | $-314.0K | $129.0K | $165.0K | $-47.0K | · | |
| Stockholders' Equity | $-132M | $45M | $150M | $217M | $253M | $332M | $98M | $132M | $-109M | |
| Liabilities + Equity | $174M | $387M | $471M | $407M | $341M | $394M | $156M | $223M | $41M | |
| Shares Outstanding | 8,584,309 | 8,306,398 | 61,009,829 | 57,499,541 | 46,327,131 | 45,752,116 | 23,098,969 | 22,848,184 | 465,330 |
Cashflow 16
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $7M | $7M | $7M | $6M | $5M | $4M | $5M | $5M | $5M | |
| Stock-based Comp | $14M | $25M | $25M | $26M | $23M | $12M | $10M | $3M | $1M | |
| Restructuring | $13M | · | · | · | · | · | · | · | · | |
| Other Non-cash | $-7M | $4M | $-37M | $91M | $-4M | $-52M | · | $41M | · | |
| Operating Cash Flow | $-177M | $-192M | $-112M | $4M | $-82M | $-68M | $-65M | $13M | $-37M | |
| CapEx | · | · | · | · | · | · | · | $2M | $3M | |
| Investing Cash Flow | $45M | $219M | $-4M | $-35M | $-97M | $604.0K | $-51M | $-80M | $33M | |
| Debt Issued | · | · | · | · | · | · | · | $0 | $15M | |
| Net Debt Issued | · | · | · | · | · | · | · | $0 | · | |
| Stock Issued | $0 | $25M | $0 | $0 | · | $251M | $-327.0K | · | · | |
| Stock Repurchased | · | · | · | · | $7.0K | · | · | · | · | |
| Net Stock Activity | $0 | $25M | $12M | $56M | $-7.0K | $251M | · | · | · | |
| Financing Cash Flow | $44.0K | $94M | $138M | $48M | $3M | $269M | $-4M | $171M | $15M | |
| Net Change in Cash | $-132M | $121M | $22M | $17M | $-176M | $202M | $-120M | $103M | $10M | |
| Taxes Paid | $75.0K | $18M | $379.0K | $0 | $103.0K | · | · | · | · | |
| Free Cash Flow | · | · | · | · | · | · | · | $11M | · |
Rentabilität 7
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -154.5% | -384.3% | -58.1% | -190.3% | -159.2% | -166.3% | · | -96.9% | · | |
| Net Margin | -186.5% | -366.6% | -69.5% | -175.9% | -170.6% | -75.2% | · | -91.9% | · | |
| Pretax Margin | -186.5% | -362.8% | -57.6% | -172.2% | · | · | · | · | · | |
| EBITDA Margin | -147.4% | -372.7% | -53.6% | -181.9% | -151.4% | -156.3% | · | -85.1% | · | |
| ROA | -68.1% | -53.0% | -24.3% | -31.9% | -28.7% | -11.7% | · | -26.8% | · | |
| ROE | 232.2% | -292.0% | -81.5% | -53.4% | -39.4% | -11.2% | · | 713.8% | · | |
| ROIC | 119.5% | -540.2% | -70.0% | -56.5% | · | · | · | · | · |
Liquidität & Solvenz 5
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.0 | 2.6 | 4.5 | 5.3 | 5.2 | 12.8 | · | 5.8 | · | |
| Quick Ratio | 1.9 | 2.5 | 3.9 | 4.7 | 4.2 | 11.2 | · | 5.7 | · | |
| Debt / Equity | · | · | 0.0 | 0.1 | 0.1 | 0.1 | · | 0.1 | · | |
| LT Debt / Equity | · | · | 0.0 | 0.0 | 0.1 | 0.1 | · | 0.1 | · | |
| Interest Coverage | · | · | · | · | · | · | · | -22.9 | · |
Effizienz 2
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.4 | 0.1 | 0.4 | 0.2 | 0.2 | 0.2 | · | 0.3 | · | |
| Receivables Turnover | 16.3 | 2.8 | 7.1 | 6.9 | 6.9 | 7.2 | · | 18.7 | · |
Wachstumsraten 3
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 65.2% | -59.6% | 126.8% | 9.5% | 44.8% | · | · | · | · | |
| Revenue CAGR 3Y | 14.8% | 0.09% | 53.2% | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 19.1% | · | · | · | · | · | · | · | · |
Bewertung (TTM) 14
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $102M | $62M | $154M | $68M | $62M | $43M | $43M | $38M | · | |
| Net Income TTM | $-191M | $-227M | $-107M | $-119M | $-106M | $-32M | $-119M | $-35M | · | |
| Market Cap | $99M | $152M | $262M | $465M | $689M | $993M | · | $206M | · | |
| Enterprise Value | · | · | $-68M | $179M | $554M | $691M | · | $12M | · | |
| P/E | -0.5 | -0.1 | -2.4 | -3.4 | -6.5 | -21.9 | · | · | · | |
| P/S | 1.0 | 2.4 | 1.7 | 6.9 | 11.1 | 23.2 | · | 5.4 | · | |
| P/B | -0.7 | 3.4 | 1.7 | 2.1 | 2.7 | 3.0 | · | 1.6 | · | |
| P / Tangible Book | · | 3.4 | 1.7 | 2.1 | 2.7 | 3.0 | · | · | · | |
| P / Cash Flow | -0.6 | -0.8 | -2.3 | 130.9 | -8.4 | -14.6 | · | 16.2 | · | |
| P / FCF | · | · | · | · | · | · | · | 18.5 | · | |
| EV / EBITDA | · | · | 0.8 | -1.4 | -5.9 | -10.4 | · | -0.4 | · | |
| EV / FCF | · | · | · | · | · | · | · | 1.0 | · | |
| EV / Revenue | · | · | -0.4 | 2.6 | 8.9 | 16.2 | · | 0.3 | · | |
| Earnings Yield | -194.4% | -1597.8% | -41.5% | -29.1% | -15.4% | -4.6% | · | · | · |
Gewinn- und Verlustrechnung 13
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $10M | $15M | $12M | $10M | $64M | $17M | $15M | $9M | $26M | $13M | $114M | $17M | $10M | $13M | $9M | $25M | |
| R&D Expense | $32M | $37M | $37M | $40M | $38M | $52M | $71M | $62M | $62M | $57M | $54M | $46M | $42M | $39M | $43M | $32M | |
| SG&A Expense | $8M | $8M | $9M | $9M | $10M | $13M | $9M | $14M | $12M | $13M | $17M | $15M | $15M | $16M | $15M | $15M | |
| Operating Expenses | $40M | $44M | $50M | $58M | $67M | $86M | $80M | $76M | $74M | $70M | $71M | $61M | $57M | $55M | $58M | $46M | |
| Operating Income | $-30M | $-30M | $-38M | $-48M | $-3M | $-69M | $-65M | $-68M | $-49M | $-57M | $43M | $-44M | $-46M | $-42M | $-49M | $-21M | |
| Pretax Income | $-39M | $-38M | $-47M | $-57M | $-12M | $-76M | $-70M | $-49M | $-48M | $-58M | $47M | $-47M | $-38M | $-50M | $-35M | $-19M | |
| Income Tax | $1.0K | $-15.0K | $-82.0K | $0 | $-18.0K | $7.0K | $2M | $0 | $8.0K | · | $16M | $2M | $151.0K | $395.0K | $0 | $0 | |
| Net Income | $-39M | $-38M | $-47M | $-57M | $-11M | $-76M | $-72M | $-49M | $-48M | $-58M | $31M | $-49M | $-39M | $-50M | $-35M | $-19M | |
| EPS (Basic) | $-2.33 | $-2.94 | $-20.77 | $-0.67 | $-1.35 | $-9.08 | $-27.63 | $-0.59 | $-0.59 | $-0.59 | $0.52 | $-0.81 | $-0.64 | $-0.85 | $-0.59 | $-0.37 | |
| EPS (Diluted) | $-2.33 | $-2.94 | $-20.77 | $-0.67 | $-1.35 | $-9.08 | $-27.63 | $-0.59 | $-0.59 | $-0.59 | $0.52 | $-0.81 | $-0.64 | $-0.85 | $-0.59 | $-0.37 | |
| Shares (Basic) | 16,571,602 | 13,082,355 | -244,058,204 | 84,869,864 | 8,511,985 | 8,364,294 | -216,989,358 | 82,043,671 | 81,224,628 | 61,457,793 | -119,498,390 | 60,599,025 | 60,339,475 | 58,723,432 | -95,063,345 | 52,345,732 | |
| Shares (Diluted) | 16,571,602 | 13,082,355 | -244,058,204 | 84,869,864 | 8,511,985 | 8,364,294 | -216,989,358 | 82,043,671 | 81,224,628 | 61,457,793 | -119,498,390 | 60,599,025 | 60,339,475 | 58,723,432 | -95,063,345 | 52,345,732 | |
| EBITDA | $-30M | $-28M | · | $-48M | $-3M | $-67M | · | $-68M | $-49M | $-55M | · | $-44M | $-46M | $-41M | · | $-21M |
Bilanz 23
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $54M | $74M | $58M | $66M | $64M | $106M | $190M | $175M | $91M | $65M | $69M | $82M | $235M | $62M | $47M | $97M | |
| Short-term Investments | $110M | $129M | $83M | $102M | $141M | $143M | $127M | $214M | $285M | $202M | $264M | $239M | $123M | $189M | · | $191M | |
| Receivables | $6M | $12M | $4M | $4M | $8M | $14M | $9M | $7M | $7M | $31M | $36M | $17M | $10M | $10M | · | $11M | |
| Prepaid Expense | $6M | $6M | $6M | $11M | $18M | $25M | $18M | $11M | $11M | $10M | $10M | $9M | $10M | $18M | · | $11M | |
| Current Assets | $176M | $221M | $151M | $182M | $232M | $287M | $343M | $406M | $443M | $355M | $422M | $381M | $412M | $304M | · | $347M | |
| PP&E (Net) | $8M | $9M | $11M | $13M | $15M | $17M | $18M | $19M | $19M | $21M | $22M | $22M | $24M | $24M | · | $24M | |
| PP&E (Gross) | · | · | $38M | · | · | · | $67M | · | · | · | $64M | · | · | · | · | · | |
| Accum. Depreciation | · | · | $27M | · | · | · | $49M | · | · | · | $42M | · | · | · | · | · | |
| Other Non-current Assets | $1M | $1M | $495.0K | $0 | $50.0K | $85.0K | $7M | $7M | $5M | $6M | $4M | $3M | $3M | $3M | · | $2M | |
| Total Assets | $194M | $242M | $174M | $210M | $262M | $321M | $387M | $452M | $489M | $403M | $471M | $432M | $465M | $358M | · | $401M | |
| Accounts Payable | $3M | $5M | $8M | $7M | $4M | $8M | $10M | $6M | $6M | $8M | $9M | $6M | $4M | $5M | · | $12M | |
| Accrued Liabilities | $6M | $5M | $15M | $13M | $12M | $12M | $13M | $13M | $10M | $7M | $15M | $11M | $10M | $6M | · | $10M | |
| Current Liabilities | $53M | $71M | $75M | $72M | $74M | $133M | $132M | $131M | $130M | $80M | $94M | $74M | $67M | $59M | · | $58M | |
| Capital Leases | $4M | $6M | $8M | $10M | $12M | $14M | $16M | $18M | $20M | $21M | $23M | $25M | $27M | $28M | · | $31M | |
| Other Non-current Liabilities | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | · | · | · | · | $133.0K | |
| Total Liabilities | $298M | $309M | $306M | $297M | $294M | $347M | $343M | $341M | $337M | $305M | $321M | $319M | $310M | $173M | · | $171M | |
| Total Debt | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | $7M | |
| Common Stock | $17.0K | $17.0K | $9.0K | $85.0K | $85.0K | $84.0K | $8.0K | $82.0K | $82.0K | $62.0K | $61.0K | $61.0K | $60.0K | $60.0K | · | $55.0K | |
| Retained Earnings | $-1.05B | $-1.02B | $-978M | $-931M | $-874M | $-863M | $-787M | $-714M | $-666M | $-618M | $-559M | $-590M | $-541M | $-503M | · | $-418M | |
| AOCI | $-58.0K | $-101.0K | $19.0K | $33.0K | $-13.0K | $-9.0K | $39.0K | $106.0K | $-163.0K | $-113.0K | $21.0K | $7.0K | $16.0K | $-107.0K | · | $-1M | |
| Stockholders' Equity | $-103M | $-67M | $-132M | $-87M | $-32M | $-26M | $45M | $111M | $152M | $98M | $150M | $112M | $155M | $185M | $217M | $230M | |
| Liabilities + Equity | $194M | $242M | $174M | $210M | $262M | $321M | $387M | $452M | $489M | $403M | $471M | $432M | $465M | $358M | · | $401M | |
| Shares Outstanding | 16,576,205 | 16,566,803 | 8,584,309 | 85,101,749 | 84,720,047 | 84,349,041 | 8,306,398 | 82,395,350 | 81,861,584 | 62,456,546 | 61,009,829 | 60,900,704 | 60,471,041 | 60,161,801 | · | 54,631,360 |
Cashflow 10
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $1M | $1M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $1M | |
| Stock-based Comp | $2M | $2M | $2M | $2M | $5M | $6M | $6M | $7M | $6M | $6M | $6M | $6M | $7M | $6M | $6M | $7M | |
| Restructuring | · | $0 | $1M | $3M | $1M | $8M | · | · | · | · | · | · | · | · | · | · | |
| Other Non-cash | · | $-7M | · | · | · | $647.0K | · | · | · | $-14M | · | · | · | $-19M | · | · | |
| Operating Cash Flow | $-38M | $-42M | $-26M | $-38M | $-45M | $-68M | $-72M | $-65M | $9M | $-65M | $14M | $-34M | $-31M | $-61M | $-24M | $66M | |
| Investing Cash Flow | $19M | $-45M | $19M | $40M | $3M | $-16M | $87M | $147M | $-80M | $64M | $-24M | $-114M | $66M | $67M | $-38M | $-78M | |
| Stock Issued | · | · | $0 | $0 | · | · | $0 | $0 | · | · | · | · | · | · | · | · | |
| Financing Cash Flow | $-418.0K | $103M | $-64.0K | $102.0K | $-60.0K | $66.0K | $-24.0K | $1M | $96M | $-3M | $-3M | $-6M | $138M | $9M | $12M | $30M | |
| Net Change in Cash | $-19M | $16M | $-8M | $2M | $-42M | $-84M | $16M | $84M | $26M | $-4M | $-13M | $-153M | $173M | $15M | $-50M | $18M | |
| Taxes Paid | $1.0K | $-15.0K | $64.0K | $0 | $4.0K | $7.0K | $2M | $2.0K | $15M | $10.0K | · | · | · | · | · | · |
Rentabilität 7
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -303.8% | -204.2% | · | -499.9% | -5.2% | -393.8% | · | -797.2% | -189.4% | -435.1% | · | -260.1% | -443.5% | -333.3% | · | -84.3% | |
| Net Margin | -391.6% | -265.0% | · | -586.6% | -18.0% | -436.6% | · | -572.6% | -186.8% | -447.5% | · | -291.2% | -370.0% | -394.9% | · | -77.5% | |
| Pretax Margin | -391.6% | -265.1% | · | -586.6% | -18.1% | · | · | -572.6% | -186.8% | -447.5% | · | -280.3% | -368.6% | -391.8% | · | -77.5% | |
| EBITDA Margin | -303.8% | -195.4% | · | -499.9% | -5.2% | -382.9% | · | -797.2% | -189.4% | -421.5% | · | -260.1% | -443.5% | -320.5% | · | -84.3% | |
| ROA | -16.9% | -13.7% | · | -17.2% | -3.1% | -21.0% | · | -11.0% | -10.1% | -15.3% | · | -11.8% | -9.1% | -15.1% | · | -5.1% | |
| ROE | 56.9% | 83.0% | · | -474.8% | -19.1% | -210.4% | · | -43.6% | -31.3% | -41.1% | · | -28.8% | -21.2% | -24.7% | · | -7.6% | |
| ROIC | 28.9% | 44.3% | · | 55.5% | 10.4% | · | · | -61.1% | -32.0% | · | · | -40.7% | -30.0% | -23.0% | · | · |
Liquidität & Solvenz 4
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.3 | 3.1 | · | 2.5 | 3.1 | 2.2 | · | 3.1 | 3.4 | 4.5 | · | 5.2 | 6.1 | 5.1 | · | 5.9 | |
| Quick Ratio | 3.2 | 3.0 | · | 2.4 | 2.9 | 2.0 | · | 3.0 | 2.9 | 3.8 | · | 4.6 | 5.5 | 4.4 | · | 5.1 | |
| Debt / Equity | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | 0.0 | |
| LT Debt / Equity | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | 0.0 |
Effizienz 2
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.0 | 0.1 | · | 0.0 | 0.2 | 0.0 | · | 0.0 | 0.1 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.1 | |
| Receivables Turnover | 1.4 | 1.1 | · | 1.8 | 8.5 | 0.8 | · | 0.7 | 3.0 | 0.6 | · | 1.2 | 0.2 | 1.2 | · | 2.1 |
Bewertung (TTM) 12
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $98M | $105M | · | $99M | $115M | $65M | · | $64M | $66M | $53M | · | $65M | $76M | $72M | · | $68M | |
| Net Income TTM | $-145M | $-183M | · | $-193M | $-184M | $-231M | · | $-204M | $-194M | $-196M | · | $-157M | $-134M | $-135M | · | $-116M | |
| Market Cap | $550M | $413M | · | $74M | $60M | $55M | · | $285M | $240M | $353M | · | $211M | $281M | $278M | · | $303M | |
| Enterprise Value | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | $23M | |
| P/E | -4.6 | -1.9 | · | -0.4 | -0.3 | -0.2 | · | -1.3 | -1.1 | -2.0 | · | -1.3 | -1.9 | -1.8 | · | -2.3 | |
| P/S | 5.6 | 3.9 | · | 0.7 | 0.5 | 0.8 | · | 4.4 | 3.6 | 6.7 | · | 3.2 | 3.7 | 3.9 | · | 4.5 | |
| P/B | -5.3 | -6.2 | · | -0.8 | -1.9 | -2.1 | · | 2.6 | 1.6 | 3.6 | · | 1.9 | 1.8 | 1.5 | · | 1.3 | |
| P / Tangible Book | · | · | · | · | · | · | · | 2.6 | 1.6 | 3.6 | · | 1.9 | 1.8 | 1.5 | · | 1.3 | |
| P / Cash Flow | · | -9.8 | · | · | · | -0.8 | · | · | · | -5.5 | · | · | · | -4.6 | · | · | |
| EV / EBITDA | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | -1.1 | |
| EV / Revenue | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | 0.3 | |
| Earnings Yield | -22.0% | -51.5% | · | -265.5% | -314.1% | -412.3% | · | -74.6% | -89.8% | -51.1% | · | -77.0% | -51.8% | -56.5% | · | -43.8% |
Finanzberichte Gewinn- und Verlustrechnung, Bilanz, Cashflow — jährlich, letzte 5 Jahre
Gewinn- und Verlustrechnung
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Umsatz | $102M | $62M | $154M | $68M | $62M |
| Betriebsgewinnmarge % | -154.5% | -384.3% | -58.1% | -190.3% | -159.2% |
| Nettoergebnis | $-191M | $-227M | $-107M | $-119M | $-106M |
| Verwässerte EPS | $-22.49 | $-29.40 | $-1.78 | $-2.35 | $-2.29 |
Bilanz
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Fremdkapital / Eigenkapital | — | — | 0.0 | 0.1 | 0.1 |
| Liquiditätsgrad | 2.0 | 2.6 | 4.5 | 5.3 | 5.2 |
| Quick Ratio | 1.9 | 2.5 | 3.9 | 4.7 | 4.2 |
Meine Kennzahlen Ihre persönliche Watchlist — ausgewählte Zeilen aus den vollständigen Fundamentaldaten
📊
Wählen Sie die Kennzahlen, die für Sie wichtig sind — klicken Sie auf das ➕ neben jeder Zeile in den vollständigen Fundamentaldaten oben.
Ihre Auswahl wird gespeichert und begleitet Sie über alle Ticker hinweg.
Institutionelle Eigentümer (13F) 111 Einreicher · $467.3M gesamt · Stand 30. Juni 2026
Institutionen, die diese Aktie in ihrer vierteljährlichen SEC-Formular 13F melden. Nur Long-Positionen; ein einzelner Einreicher kann für separate Optionsscheine zweimal erscheinen. Große gegenläufige Put/Call-Positionen spiegeln typischerweise Market-Making oder abgesicherte Bestände wider, nicht die gerichtete Überzeugung.
Institutionelle Aktivität — Q2 2026 vs. Vorquartal
| Neue Positionen | Geschlossene Positionen | Erhöht | Abgenommen | Nettoveränderung der Aktien |
|---|---|---|---|---|
| 46 (+21 vs. Vorquartal) | 16 (+8 vs. Vorquartal) | 20 (0 vs. Vorquartal) | 19 (+5 vs. Vorquartal) | +1.3M |
Verglichen mit Q1 2026. SEC-Formular 13F-Einreichungen sind innerhalb von 45 Tagen nach Quartalsende fällig, zuzüglich einer kurzen Pufferzeit für verspätete Einreicher — Quartale, die noch in diesem Fenster liegen, werden zugunsten des letzten vollständig berichteten Paares übersprungen.
| Institution | Wert | Aktien | % der verfolgten 13F | Typ |
|---|---|---|---|---|
| PERCEPTIVE ADVISORS LLC | $43.320.887 | 1.304.846 | 9,27% | Aktien |
| BVF INC/IL | $41.559.362 | 1.251.788 | 8,89% | Aktien |
| Affinity Asset Advisors, LLC | $38.926.568 | 1.172.487 | 8,33% | Aktien |
| SAMSARA BIOCAPITAL, LLC | $35.287.350 | 1.062.872 | 7,55% | Aktien |
| Kynam Capital Management, LP | $28.968.926 | 872.558 | 6,20% | Aktien |
| ORBIMED ADVISORS LLC | $24.698.941 | 743.944 | 5,29% | Aktien |
| Balyasny Asset Management L.P. | $23.610.578 | 711.162 | 5,05% | Aktien |
| VANGUARD CAPITAL MANAGEMENT LLC | $23.048.071 | 694.219 | 4,93% | Aktien |
| EVENTIDE ASSET MANAGEMENT, LLC | $19.430.698 | 585.262 | 4,16% | Aktien |
| Velan Capital Investment Management LP | $17.003.712 | 512.160 | 3,64% | Aktien |
| Woodline Partners LP | $15.206.563 | 458.029 | 3,25% | Aktien |
| ADAR1 Capital Management, LLC | $13.413.265 | 404.014 | 2,87% | Aktien |
| MILLENNIUM MANAGEMENT LLC | $12.150.270 | 365.972 | 2,60% | Aktien |
| GEODE CAPITAL MANAGEMENT, LLC | $11.027.500 | 332.057 | 2,36% | Aktien |
| STATE STREET CORP | $10.158.503 | 305.979 | 2,17% | Aktien |
| Merck & Co., Inc. | $9.042.053 | 272.351 | 1,93% | Aktien |
| ACUTA CAPITAL PARTNERS, LLC | $8.972.333 | 270.251 | 1,92% | Aktien |
| AMERIPRISE FINANCIAL INC | $8.123.011 | 244.669 | 1,74% | Aktien |
| Point72 Asset Management, L.P. | $7.895.856 | 237.827 | 1,69% | Aktien |
| KVP Capital Advisors, LP | $7.522.290 | 226.575 | 1,61% | Aktien |
| TWO SIGMA INVESTMENTS, LP | $6.696.042 | 201.688 | 1,43% | Aktien |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $6.559.058 | 197.562 | 1,40% | Aktien |
| UBS Group AG | $5.407.251 | 162.869 | 1,16% | Aktien |
| Seven Fleet Capital Management LP | $3.794.182 | 159.118 | 0,81% | Aktien |
| Qube Research & Technologies Ltd | $3.539.452 | 106.610 | 0,76% | Aktien |
| VANGUARD FIDUCIARY TRUST CO | $3.460.502 | 104.232 | 0,74% | Aktien |
| CITADEL ADVISORS LLC | $3.385.205 | 101.964 | 0,72% | Aktien |
| MACKENZIE FINANCIAL CORP | $3.146.264 | 94.767 | 0,67% | Aktien |
| RENAISSANCE TECHNOLOGIES LLC | $2.865.957 | 86.324 | 0,61% | Aktien |
| MARSHALL WACE, LLP | $2.448.865 | 73.761 | 0,52% | Aktien |
| Y-Intercept (Hong Kong) Ltd | $1.855.183 | 55.879 | 0,40% | Aktien |
| Squarepoint Ops LLC | $1.843.895 | 55.539 | 0,39% | Aktien |
| XTX Topco Ltd | $1.732.011 | 52.169 | 0,37% | Aktien |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $1.636.826 | 49.302 | 0,35% | Aktien |
| Sigma Planning Corp | $1.494.664 | 45.020 | 0,32% | Aktien |
| Fisher Asset Management, LLC | $1.171.794 | 35.295 | 0,25% | Aktien |
| Elmind Capital, LP | $1.063.628 | 32.037 | 0,23% | Aktien |
| D. E. Shaw & Co., Inc. | $1.000.250 | 30.128 | 0,21% | Aktien |
| GOLDMAN SACHS GROUP INC | $975.814 | 29.392 | 0,21% | Aktien |
| Trexquant Investment LP | $917.515 | 27.636 | 0,20% | Aktien |
| BNP PARIBAS FINANCIAL MARKETS | $909.116 | 27.383 | 0,19% | Aktien |
| BANK OF AMERICA CORP /DE/ | $863.897 | 26.021 | 0,18% | Aktien |
| RHUMBLINE ADVISERS | $684.845 | 20.628 | 0,15% | Aktien |
| JPMORGAN CHASE & CO | $625.079 | 18.743 | 0,13% | Aktien |
| BlackRock, Inc. | $595.276 | 17.930 | 0,13% | Aktien |
| SEI INVESTMENTS CO | $544.048 | 16.387 | 0,12% | Aktien |
| Informed Momentum Co LLC | $538.902 | 16.232 | 0,12% | Aktien |
| DEUTSCHE BANK AG\ | $516.692 | 15.563 | 0,11% | Aktien |
| RBF Capital, LLC | $507.030 | 15.272 | 0,11% | Aktien |
| WELLS FARGO & COMPANY/MN | $449.661 | 13.544 | 0,10% | Aktien |
| AJU IB Investment Co., Ltd. | $435.925 | 17.500 | 0,09% | Aktien |
| Bank of New York Mellon Corp | $434.522 | 13.088 | 0,09% | Aktien |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $368.520 | 11.100 | 0,08% | Kaufoption |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $365.200 | 11.000 | 0,08% | Verkaufsoption |
| MetLife Investment Management, LLC | $312.113 | 9.401 | 0,07% | Aktien |
| Walleye Capital LLC | $308.959 | 9.306 | 0,07% | Aktien |
| Integrated Quantitative Investments LLC | $296.775 | 8.939 | 0,06% | Aktien |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $279.743 | 8.426 | 0,06% | Aktien |
| Lighthouse Investment Partners, LLC | $277.818 | 8.368 | 0,06% | Aktien |
| MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. | $242.792 | 7.313 | 0,05% | Aktien |
| ALLIANCEBERNSTEIN L.P. | $242.360 | 7.300 | 0,05% | Aktien |
| STATE BOARD OF ADMINISTRATION OF FLORIDA RETIREMENT SYSTEM | $232.433 | 7.001 | 0,05% | Aktien |
| Persistent Asset Partners Ltd | $218.091 | 6.569 | 0,05% | Aktien |
| CITIGROUP INC | $216.995 | 6.536 | 0,05% | Aktien |
| Verdad Advisers, LP | $212.480 | 6.400 | 0,05% | Aktien |
| Invesco Ltd. | $211.119 | 6.359 | 0,05% | Aktien |
| HSBC HOLDINGS PLC | $205.722 | 6.234 | 0,04% | Aktien |
| TWO SIGMA ADVISERS, LP | $203.401 | 17.580 | 0,04% | Aktien |
| NEW YORK STATE COMMON RETIREMENT FUND | $185.920 | 5.600 | 0,04% | Aktien |
| MORGAN STANLEY | $181.870 | 5.478 | 0,04% | Aktien |
| Vanguard Global Advisers, LLC | $180.774 | 5.445 | 0,04% | Aktien |
| Police & Firemen's Retirement System of New Jersey | $156.173 | 4.704 | 0,03% | Aktien |
| Nuveen, LLC | $131.837 | 3.971 | 0,03% | Aktien |
| WELLINGTON MANAGEMENT GROUP LLP | $119.520 | 3.600 | 0,03% | Aktien |
| Nuveen Asset Management, LLC | $103.678 | 56.347 | 0,02% | Aktien |
| BARCLAYS PLC | $84.228 | 2.537 | 0,02% | Aktien |
| NORTHERN TRUST CORP | $83.100 | 2.503 | 0,02% | Aktien |
| State of Wyoming | $53.718 | 1.618 | 0,01% | Aktien |
| Legal & General Group Plc | $51.394 | 1.548 | 0,01% | Aktien |
| Ameritas Investment Partners, Inc. | $48.074 | 1.448 | 0,01% | Aktien |
| FMR LLC | $44.388 | 1.337 | 0,01% | Aktien |
| Russell Investments Group, Ltd. | $42.330 | 1.275 | 0,01% | Aktien |
| VANGUARD GROUP INC | $36.307 | 3.138 | 0,01% | Aktien |
| Tower Research Capital LLC (TRC) | $28.751 | 866 | 0,01% | Aktien |
| Point72 Asia (Singapore) Pte. Ltd. | $26.943 | 31.026 | 0,01% | Aktien |
| CWM, LLC | $24.487 | 983 | 0,01% | Aktien |
| ROYAL BANK OF CANADA | $23.000 | 687 | 0,00% | Aktien |
| Owl Creek Wealth Partners LLC | $16.302 | 491 | 0,00% | Aktien |
| ACADIAN ASSET MANAGEMENT LLC | $12.405 | 373.839 | 0,00% | Aktien |
| Sterling Capital Management LLC | $9.329 | 281 | 0,00% | Aktien |
| Quantbot Technologies LP | $6.673 | 201 | 0,00% | Aktien |
| Physician Wealth Advisors, Inc. | $6.043 | 182 | 0,00% | Aktien |
| MERCER GLOBAL ADVISORS INC /ADV | $3.718 | 112 | 0,00% | Aktien |
| OSAIC HOLDINGS, INC. | $3.320 | 100 | 0,00% | Aktien |
| PNC Financial Services Group, Inc. | $2.058 | 62 | 0,00% | Aktien |
| Fortitude Family Office, LLC | $1.859 | 56 | 0,00% | Aktien |
| Bogart Wealth, LLC | $1.660 | 50 | 0,00% | Aktien |
| Parallel Advisors, LLC | $1.560 | 47 | 0,00% | Aktien |
| NISA INVESTMENT ADVISORS, LLC | $1.461 | 44 | 0,00% | Aktien |
| Accredited Wealth Management, LLC | $869 | 5 | 0,00% | Aktien |
Unternehmensinsider 27 Insider · 14 Führungskräfte · 14 Direktoren
| Insider | Rolle | Letzte Aktivität | Gehaltene Aktien | Käufe 12m | Verkäufe 12m | Netto 12m |
|---|---|---|---|---|---|---|
| William J Newell | CEO | 3. März 2023 M | 164.816 | 0 | 0 | $0 |
| Gregory K. Chow | CFO | 2. Juni 2026 M | 4.725 | 0 | 0 | $0 |
| Edward C Albini | CFO and Secretary | 3. März 2023 M | 87.693 | 0 | 0 | $0 |
| Jane Chung | President and COO | 1. Dezember 2023 A | 31.698 | 0 | 0 | $0 |
| Hans-Peter Gerber | Chief Scientific Officer | 18. September 2023 A | — | 0 | 0 | $0 |
| Brunilda Shtylla | Chief Business Officer | 28. August 2023 S | 0 | 0 | 0 | $0 |
| Nicki Vasquez | Chief Port. Strat & Alnce Ofcr | 12. Juli 2023 M | 24.988 | 0 | 0 | $0 |
| Venkatesh Srinivasan | Chief Tech Op Officer | 1. Mai 2023 A | — | 0 | 0 | $0 |
| Trevor Hallam | Pres. Rsrch & Cf. Sctific Ofcr | 14. April 2023 M | 100.368 | 0 | 0 | $0 |
| Anne Elizabeth Borgman | Chief Medical Officer | 15. März 2023 A | — | 0 | 0 | $0 |
| Anik Shabbir | Chief Technical Ops. Officer | 3. März 2023 M | 40.827 | 0 | 0 | $0 |
| Linda A Fitzpatrick | Chief People & Comm. Officer | 3. März 2023 M | 52.690 | 0 | 0 | $0 |
| Arturo Molina MD | Chief Medical Officer | 5. März 2022 M | 37.736 | 0 | 0 | $0 |
| Stephen Worsley | Chief Business Officer | 29. Januar 2019 A | — | 0 | 0 | $0 |
| Heidi Hunter | Direktor | 5. Juni 2026 A | — | 0 | 0 | $0 |
| Michael Dybbs | Direktor | 5. Juni 2026 A | — | 0 | 0 | $0 |
| Jon Marc Wigginton | Direktor | 5. Juni 2026 A | — | 0 | 0 | $0 |
| Sukhi Jagpal | Direktor | 5. Juni 2026 A | — | 0 | 0 | $0 |
| Joseph M Lobacki | Direktor | 5. Juni 2026 A | — | 0 | 0 | $0 |
| Daniel H Petree | Direktor | 5. Juni 2026 A | 18.601 | 0 | 0 | $0 |
| Connie Matsui | Direktor | 5. Juni 2026 A | 50.000 | 1 | 0 | $40.000 |
| James P Panek | Direktor | 5. Juni 2026 A | — | 0 | 0 | $0 |
| John Gordon Freund | Direktor | 8. Juni 2023 A | 56.327 | 0 | 0 | $0 |
| Shalini Sharp | Direktor | 6. Juni 2022 A | — | 0 | 0 | $0 |
| Daniel Janney | Direktor | 17. Juni 2019 A | 1.944.901 | 0 | 0 | $0 |
| Michael Jay Ross | Direktor | 1. Oktober 2018 C | 18.248 | 0 | 0 | $0 |
| Bryan V Lawlis | Direktor | 26. September 2018 A | — | 0 | 0 | $0 |
Insider aus SEC-Einreichungen Form 3/4/5; Netto = nur P/S aus offenen Märkten
Aktivisten & 5%+-Eigentümer 1 Beteiligung
Investoren mit SEC Schedule 13D — wirtschaftliches Eigentum über 5% mit der Absicht, Einfluss auf den Emittenten zu nehmen (aktivistische Beteiligungen, Board-Kampagnen, M&A). Jede Zeile zeigt den zuletzt bekannten Stand der Position dieses Melders.
| Anmelder | Eingereicht | Beteiligung | Status | Zweck | Einreichung |
|---|---|---|---|---|---|
| SVLSF V, LLC, SV Life Sciences Fund V, L.P., SV Life Sciences Fund V Strategic Partners, L.P., SV Life Sciences Fund V (GP), L.P., ILSF III, LLC, International Life Sciences Fund III (GP), L.P., International Life Sciences Fund III Co-Investment, L.P., International Life Sciences Fund III (LP1), L.P., International Life Sciences Fund III Strategic Partners, L.P. | 9. Oktober 2018 | — | Erste Einreichung | — | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
ETF-Besitz Gehalten von 15 ETFs
Gewichtung spiegelt nur direkte Aktienbestände (N-PORT) wider; gehebelte oder derivatbasierte Fonds können zusätzliche Swap-Exposure halten, die hier nicht angezeigt wird.
| Fonds | Gewicht | Anteile | Stand | Quelle |
|---|---|---|---|---|
| QQQS · Invesco Exchange-Traded Fund Trust … | 0,43% | 3.826 SH | 8. August 2026 | Täglich |
| OMFS · Invesco Exchange-Traded Self-Indexe… | 0,25% | 28.745 SH | 8. August 2026 | Täglich |
| IWC · iShares Trust | 0,09% | 54.216 SH | 8. August 2026 | Täglich |
| VTWV · VANGUARD SCOTTSDALE FUNDS | 0,03% | 11.715 SH | 8. August 2026 | Täglich |
| IWN · iShares Trust | 0,02% | 121.308 SH | 8. August 2026 | Täglich |
| VTWO · VANGUARD SCOTTSDALE FUNDS | 0,02% | 91.894 SH | 8. August 2026 | Täglich |
| PRFZ · Invesco Exchange-Traded Fund Trust | 0,01% | 16.520 SH | 8. August 2026 | Täglich |
| IWM · iShares Trust | 0,01% | 398.610 SH | 8. August 2026 | Täglich |
| VXF · VANGUARD INDEX FUNDS | 0,01% | 177.152 SH | 8. August 2026 | Täglich |
| VHT · VANGUARD WORLD FUND | 0,01% | 47.358 SH | 8. August 2026 | Täglich |
| IWO · iShares Trust | 0,00% | 22.665 SH | 8. August 2026 | Täglich |
| ITOT · iShares Trust | 0,00% | 29.451 SH | 8. August 2026 | Täglich |
| VTI · VANGUARD INDEX FUNDS | 0,00% | 501.524 SH | 8. August 2026 | Täglich |
| VTWG · VANGUARD SCOTTSDALE FUNDS | 0,00% | 2.670 SH | 8. August 2026 | Täglich |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0,00% | 1.330 SH | 8. August 2026 | Täglich |